Skip to Content

Posts tagged with "Toxicology"

  • Animal Testing

    A Terrific Paper on the Problems in Drug Discovery

    Here’s a really interesting paper from consultants Jack Scannell and Jim Bosley in PLoS ONE, on the productivity crisis in drug discovery. Several things distinguish it: for one, it’s not just another “whither the drug industry” think piece, of which we have plenty already. This one get quantitative, attempting to figure out… Read More
  • Business and Markets

    Arguing About Zafgen’s Chances

    It’s been a wild ride for Zafgen and those following the company, and things are nowhere near over. Back in December, it became clear that two patients had died in their clinical trial of beloranib against Prader-Willi syndrome, which was clearly very bad news. But this month, the company released the rest of the data… Read More
  • Alzheimer's Disease

    A Dietary Cause for a Neurodegenerative Disease

    This is an interesting paper in itself, and its potential implications are even more so. The authors, from the Institute for Ethnomedicine and the University of Miami, have been studying a neurodegenerative condition found among Chamorro villagers on the island of Guam. The disease (Guamanian amyotrophic lateral sclerosis/parkinsonism dementia comp… Read More
  • Clinical Trials

    Big Trouble For Zafgen and Beloranib

    Zafgen went through a very rough patch back in October when it turned out that a patient in their key Phase III trial in Prader-Willi syndrome died. P-W patients have severe health problems and shortened lifespan, but the question was naturally whether the company’s investigational drug beloranib was a factor. The seemingly slow disclosure of… Read More
  • Cancer

    Another Funny-Looking Structure Comes Through

    Here’s one that I certainly wouldn’t have thought about doing. This recent paper in ACS Medicinal Chemistry Letters describes changing the substituents off the core of a PAK1 inhibitor. Nothing too interesting about that, you’d think: the inhibitor itself is one of your standard-looking kinase inhibitor sausage strings of heteroar… Read More
  • Clinical Trials

    The Wildly Unlikely Return of TGN1412

    You may be familiar with the bizarre story of TGN1412, an immunotherapy developed (briefly) by a small German company called TeGenero in 2006. This led to the infamous Phase I incident in England where a set of six volunteers were dosed at fifteen-minute intervals, but right after the last one got the injection, the first… Read More
  • Cardiovascular Disease

    PCSK9 In the Details

    The PCSK9 inhibitors are a class of drugs from which great things are expected. The first ones hitting the market are antibodies, and blocking this enzyme, which is involved in cholesterol homeostasis, clearly has major effects on circulating LDL levels. There are a lot of approaches to going after this target, in the lab, the… Read More
  • Drug Development

    Modeling the Rats, Who Model the Humans

    When you get down to it, one of the biggest problems in drug discovery is that there is (in most cases) no alternative but doing things the hard way. If you want to find out if your drug is going to work for a given disease, there’s no other way to be sure than to… Read More
  • Alzheimer's Disease

    Two Alzheimer’s Updates (Lilly and TauRx)

    When you look at the stock charts of the major pharma companies, there’s not a lot of excitement to be had. Until you get to Eli Lilly, that is. Over the last year, the S&P 500 is up about 5%, and most of the big drug stocks are actually negative (Merck -0.4%, Sanofi down 6%… Read More
  • Drug Assays

    The End of Compound Property Optimization Is At Hand

    Here’s another Big Retrospective Review of drug pipeline attrition. This sort of effort goes back to the now-famous Rule-of-Five work, and readers will recall the Pfizer roundup of a few years back, followed by an AstraZeneca one (which didn’t always recapitulate the Pfizer pfindings, either). This latest is a joint effort to look at th… Read More
...345...